Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct 3;5(10):e2238867.
doi: 10.1001/jamanetworkopen.2022.38867.

Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19

Davey M Smith  1 , Jonathan Z Li  2 , Carlee Moser  3 , Eunice Yeh  3 , Judith S Currier  4 , Kara W Chew  4 , Michael D Hughes  5 ; ACTIV-2/A5401 Study Team
Collaborators, Affiliations

Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19

Davey M Smith et al. JAMA Netw Open. .
No abstract available

Plain language summary

This cohort study of US adults with untreated COVID-19 examines the types and length of symptoms experienced following symptom recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Smith reported receiving personal fees from consulting work for Linear Therapies, Model Medicines, Kiadis Pharmaceutical, Bayer Pharmaceuticals, Signant Health, Evidera, Fluxergy, Vx Bioscience, and Pharma Holdings outside the submitted work. Dr Li reported receiving grants from Merck outside the submitted work. Dr Currier reported receiving personal fees for advisory board work from Merck and Company outside the submitted work. Dr Chew reported receiving research funding to her institution from Merck Sharp & Dohme, and reported consulting work for Pardes Biosciences; she reported having a patent pending for ACTIV-2 COVID-19 acute and long-term symptom diaries that will be made available at no cost, as they were developed with federal funding. No other disclosures were reported.

Figures

Figure.
Figure.. Self-reported Symptoms and Their Severity, Experienced by Participants Who Had At Least 2 Consecutive Days with All Targeted Symptoms Absent
Boxes indicate each day on which participants recorded in their diary at least 1 of 13 targeted symptoms being present at a self-reported severity of mild, moderate, or severe. The color of the box reflects the worst symptom severity reported of all symptoms recorded as being present. No participants reported severe symptoms after being symptom free for 2 days. Most recurrent symptoms were self-reported as mild.
See this image and copyright information in PMC

References

    1. Carlin AF, Clark AE, Chaillon A, et al. . Virologic and immunologic characterization of COVID-19 recrudescence after nirmatrelvir/ritonavir treatment. Clin Infect Dis. Published online June 20, 2022. doi:10.1093/cid/ciac496 - DOI - PMC - PubMed
    1. Charness ME, Gupta K, Stack G, et al. . Rebound of SARS-CoV-2 infection after nirmatrelvir-ritonavir treatment. N Engl J Med. 2022;387:1045-1047. doi:10.1056/NEJMc2206449 - DOI - PMC - PubMed
    1. Boucau J, Uddin R, Marino C, et al. . Characterization of virologic rebound following nirmatrelvir-ritonavir treatment for COVID-19. Clin Infect Dis. Published online June 23, 2022. doi:10.1093/cid/ciac512 - DOI - PMC - PubMed
    1. Chew KW, Moser C, Daar ES, et al. ; ACTIV-2/A5401 Study Team . Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19. Nat Commun. 2022;13(1):4931. doi:10.1038/s41467-022-32551-2 - DOI - PMC - PubMed
    1. Viana R, Moyo S, Amoako DG, et al. . Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. Nature. 2022;603(7902):679-686. doi:10.1038/s41586-022-04411-y - DOI - PMC - PubMed